This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $500 Savings Ends In:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
December 4 - 8, 2022
Marriott Marquis San DiegoDelivered as a Hybrid Event

Scott Tagawa, MD
Professor of Medicine and Professor of Medicine in Urology at Weill Cornell Medicine

Profile

Scott T. Tagawa, MD, MS, FACP is a Professor of Medicine and Professor of Medicine in Urology at Weill Cornell Medicine, and an Attending Physician at NewYork-Presbyterian – Weill Cornell Medical Center.

After earning his BS from Georgetown University, Dr. Tagawa received his MD at the University of Southern California School of Medicine. After completing his Internship and Residency training there, he became Chief Resident and subsequently underwent fellowship training in Hematology and Medical Oncology, being appointed Chief Fellow for his final two years.  He had the opportunity to train with international leaders in Genitourinary (GU) Oncology. In 2005, he was appointed Assistant Professor of Medicine at Mount Sinai School of Medicine, serving as Associate Program Director for the Fellowship Training Program. As Director of Genitourinary Oncology for the Division of Hematology and Oncology and Director of Medical Oncology for the Deane Prostate Health and Research Center, Dr. Tagawa took the lead in developing genitourinary clinical trials. He was recruited to Weill Cornell Medical College in 2007. As the Medical Director of the Genitourinary Oncology Research Program, Dr. Tagawa leads clinical trials in the areas of prostate, bladder, and kidney cancer as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development in GU malignancies with a particular interest cell-surface targeting, including prostate-specific membrane antigen (PSMA) theranostics. Dr. Tagawa also serves as co-Leader of the Experimental Therapeutics Program and Leader of the GU Disease Management Team of the Meyer Cancer Center. He is the WCM principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a funded member of the Genitourinary Committee. He has been a member of the Clinical Practice Guidelines Committee and is currently Chair of the Evidence Based Medicine Committee of the American Society of Clinical Oncology (ASCO). Additionally, he serves on the editorial boards of many journals, is a member of numerous national and international medical and scientific societies, and has been named on multiple “top doctor” award lists.


Agenda Sessions

  • PSMA-targeted Antibody-delivered Radionuclides: From Beta to Alpha

    2:30pm